Clinical trials: Genital Infection
Human Immunodeficiency Virus
Package of Resources for Assisted Contact Tracing: Implementation, Costs, and Effectiveness
Having health workers assist HIV-infected persons with the recruitment and testing of their sexual contacts and biological children is an effective and efficient way of identifying additional HIV-infected persons in need of HIV…
- Trial name
- PRACTICE (NCT05343390)
- Testing
- Enhanced implementation package, Standard implementation package
- Where
- 33 sites in Malawi
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Body Composition Sub-study of the D2EFT Trial
This is a non-randomised, controlled, parallel group, sub-study of D2EFT (NCT03017872), a randomised, open-label study in approximately 1,000 HIV-infected adults failing first-line antiretroviral therapy (ART) in low-middle…
- Trial name
- NCT03675815
- Testing
- Darunavir (DRV) 800 milligram (MG) Oral Tablet, Ritonavir 100 MG Oral Tablet, N(t)RTIs
- Where
- 7 sites in India, Malaysia and 3 more
- Volunteers
- 155 people
- Sponsor
- Kirby Institute
HIV, HIV/AIDS
Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)
This study will evaluate the safety, tolerability and innate immune mechanisms activation following administration of the combination of Pegylated Interferon alpha 2b (peg-IFN-α2b) with two broadly neutralizing antibodies…
- Conditions
- HIV, HIV/AIDS, HIV-1 Infection
- Trial name
- BEAT-2 (NCT03588715)
- Testing
- Pegylated Interferon alpha 2b (peg-IFN-α2b), 3BNC117 + 10-1074
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Luis Montaner
AIDS, HIV Infections
CSP #512 - Options in Management With Anti-Retrovirals
This 'pragmatic' trial is a 2X2 open randomized study of patients in advanced HIV disease who have failed on conventional Highly Active Antiretroviral Therapy (HAART) regimens including all three classes of anti-HIV drugs.
- Trial name
- OPTIMA (NCT00050089)
- Testing
- No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP, Standard ART vs Mega ART
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 368 people
- Sponsor
- US Department of Veterans Affairs
Papillomavirus Infections
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.
- Trial name
- NCT00157950
- Testing
- Gardasil™
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Infection, Health Behavior
HPV Vaccination Health-promotion Programme on Vaccine Acceptance and Uptake Among Female Adolescents
The MDL-SHPVP will be developed and a clustered randomised controlled trial will be conducted to evaluate the effects of the MDL-SHPVP and to examine whether the effect of the MDL-SHPVP on the rate of HPV vaccine uptake 1 year…
- Conditions
- HPV Infection, Health Behavior, Health Attitude
- Trial name
- NCT04438291
- Testing
- MDL-SHPVP, 30-minute educational video
- Where
- Hong Kong
- Volunteers
- 1,340 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Infection, Human Immunodeficiency Virus
Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations
This trial is a randomized, double-blind, placebo-controlled clinical study conducted in treatment-experienced adults with NNRTI-resistant HIV-1, designed to preliminarily evaluate the efficacy, safety, and resistance profile of…
- Trial name
- NCT07711210
- Testing
- ACC017
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu Aidea Pharmaceutical Group Co., Ltd.
HIV Infections
MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection
The purpose of this research study is to see if HIV that persists despite current antiviral therapy can be targeted by new treatments.
- Trial name
- NCT00614458
- Testing
- Raltegravir; valproic acid
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of North Carolina, Chapel Hill
Vaginosis, Bacterial
Safety and Tolerability of Metronidazole Gel 1.3%
Multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal Gel in females 12 to <18 years for the treatment of bacterial vaginosis.
- Trial name
- NCT02392026
- Testing
- Metronidazole Gel
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Insud Pharma
HIV Infections
Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients
Primary Objectives 1.Evaluation of safety and tolerability after repeated administration of injectable Lipivirtide in HIV-infected patients not receiving antiretroviral therapy Secondary Objectives 1.
- Trial name
- NCT05349968
- Testing
- Lipovirtide for injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanxi Kangbao Biological Product Co., Ltd.
HIV Infections
The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors
The purpose of this study is to see if it is safe and effective to give 1592U89 plus 141W94 plus DMP 266 to patients with HIV who have developed resistance to indinavir, ritonavir, saquinavir, or nelfinavir after at least 20…
- Trial name
- NCT00002213
- Testing
- Abacavir sulfate, Amprenavir, Efavirenz
- Where
- 9 sites in United States
- Volunteers
- 80 people
- Sponsor
- Glaxo Wellcome
HIV
Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community
The federal research award entitles "Long-acting injectable antiretroviral treatment to improve HIV treatment among justice-involved persons being released to the community" aims to Conduct interviews with justice and treatment…
- Trial name
- NCT06704204
- Testing
- The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks
- Volunteers
- 20 people
- Sponsor
- The Miriam Hospital
Cytomegalovirus Infections, HIV Infections
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients
PRIMARY: To evaluate the efficacy of valacyclovir hydrochloride (BW 256U87) in the prevention of cytomegalovirus (CMV) end-organ disease in HIV/CMV co-infected patients with CD4+ lymphocytes < 100 cells/mm3.
- Trial name
- NCT00001038
- Testing
- Valacyclovir hydrochloride, Acyclovir
- Where
- 35 sites in United States, Australia and 8 more
- Volunteers
- 1,200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Tuberculosis
Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women
Tuberculosis (TB) is a leading cause of death among HIV-infected persons in low-income settings and can be a serious complication for HIV-infected pregnant women and their infants.
- Trial name
- NCT01494038
- Testing
- Isoniazid (INH)
- Where
- 13 sites in Botswana, Haiti and 6 more
- Volunteers
- 956 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infections, Papillomavirus
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. The infection of the cervix by certain oncogenic types of HPV, if not cleared, can lead to cervical cancer in women.
- Trial name
- NCT00485732
- Testing
- HPV-16/18 VLP/AS04 vaccine (Cervarix TM)
- Where
- 6 sites in South Korea
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections, Hepatitis B
Project UNITY - HIV Risk Reduction and Vaccine Education Interventions
To determine the efficacy of an enhanced HIV risk reduction intervention delivered concurrently with a vaccination schedule to reduce the number of unprotected vaginal and anal sex acts among HIV-negative, high-risk non-injection…
- Trial name
- NCT00150098
- Testing
- Enhanced HIV risk reduction and HIV vaccine education
- Where
- 2 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- New York Blood Center
HIV Infections
Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens
Impact of Maraviroc, a ART CCR5 inhibitor, on the intensification of immune function in HIV-1 infected subjects receiving immunisation with novel antigens The purpose of the study is to investigate the impact of adding Maraviroc…
- Trial name
- NCT01049204
- Testing
- Maraviroc
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- St Stephens Aids Trust
HIV Infections, Adherence
Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens
The study is recruiting 50 patients initiating or switching to Atripla and comparing them to 250 individuals previously followed in a prospective study of HIV+ low income individuals recruited from homeless shelters, single room…
- Trial name
- NCT01006005
- Volunteers
- 51 people
- Sponsor
- University of California, San Francisco
Treponema Pallidum Infection, Chlamydia Trachomatis Infection
Improving Maternal and Child Health Through Point-of-care STI Testing
The goal of this clinical trial is to learn if point-of-care tests (POCTs) for sexually transmitted infections (STIs) improve the timely treatment of syphilis, chlamydia, gonorrhea, and trichomonas in pregnant women.
- Conditions
- Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginalis Vaginitis
- Trial name
- MATCH-POINT (NCT07290439)
- Testing
- Point-of-care STI tests, Standard of care STI testing
- Where
- United States
- Volunteers
- 756 people, healthy volunteers welcome
- Sponsor
- Emory University
HIV Infections
A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIV
The study aims to evaluate the safety, tolerability and pharmacokinetic (PK) properties of a single dose of VH5356136 in adult participants without human immunodeficiency virus (HIV).
- Trial name
- NCT07822477
- Testing
- VH5356136 Formulation 1, VH5356136 Formulation 2
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.